Noradrenaline and extracellular nucleotide cotransmission involves activation of vasoconstrictive P2X1,3‐ and P2Y6‐like receptors in mouse perfused kidney
- 1 May 2005
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 145 (1) , 66-74
Abstract
Nucleotides like ATP and UTP act as potent extracellular signalling molecules. Released from sympathetic nerve endings as cotransmitters of noradrenaline or paracrine from nonexcitatory cells, they activate specific receptors (ion‐gated P2X1–7 and G‐protein‐coupled P2Y1,2,4,6,11–15). Which of these subtypes, however, are able to modulate vasoconstriction in the kidney is unclear. Wild‐type‐ and P2Y4‐receptor‐deficient mice kidneys were isolated and perfused with Krebs–Henseleit solution. Pressor responses to renal nerve stimulations (RNS) and added drugs were recorded. Release of endogenous noradrenaline was measured by HPLC. RNS (1–15 Hz) induced a frequency‐dependent increase in the perfusion pressor (14.2±5.1–67.3±6.9 mmHg) and noradrenaline release (1.4±0.3–24.2±3.4 ng g−1 kidney). Pressor responses to RNS were not (1–2 Hz) or only partially (5–15 Hz) blocked by the α‐adrenoceptor antagonist phentolamine (1 μM). Combination of phentolamine and the P2‐receptor blocker PPADS (5 μM) prevented RNS‐induced pressor responses. The P2X1,3‐receptor selective antagonist NF279 (10 μM) reduced RNS‐induced pressor responses in a frequency‐dependent manner. Perfusion of ATP, ADP, UTP, UDP and α,β‐meATP concentration dependently increased perfusion pressor with the following rank order of potency α,β‐meATP>ADP≈ATP≈UDPUTP. NF279 (10 μM) reduced α,β‐meATP‐ (0.1 μM) (21.7±3.9% of control) but not UTP‐ (0.3 μM) (102.6±15.3% of control) induced pressor responses. No differences in nucleotide‐induced effects were detected among wild‐type and P2Y4‐receptor knockout mice. Continuous perfusion of α,β‐meATP (0.01 μM) potentiated UTP‐, UDP‐ and ATP‐γS‐induced pressor responses. Neuronally and paracrine‐released nucleotides evoked renal vasoconstriction by activation of P2X1,3‐ and P2Y6‐like receptors in mice. Pretreatment with the P2X1,3‐receptor agonist α,β‐meATP potentiated P2Y6‐like receptor‐mediated vasoconstrictions. British Journal of Pharmacology (2005) 145, 66–74. doi:10.1038/sj.bjp.0706151Keywords
This publication has 30 references indexed in Scilit:
- P2 Purinoceptors: Historical Perspective and Classification2007
- α,β-Methylene ATP enhances P2Y4 contraction of rabbit basilar arteryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- P2Y‐Receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathwayBritish Journal of Pharmacology, 2003
- The stable pyrimidines UDPβS and UTPγS discriminate between contractile cerebrovascular P2 receptorsEuropean Journal of Pharmacology, 2002
- ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cellsKidney International, 2002
- Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal DiseaseCirculation, 2002
- P2 purinoceptor‐mediated control of rat cerebral (pial) microvasculature; contribution of P2X and P2Y receptorsThe Journal of Physiology, 2000
- Purinoceptors mediate renal vasodilation by nitric oxide dependent and independent mechanismsKidney International, 1998
- Purinergic Signalling: Pathophysiological RolesThe Japanese Journal of Pharmacology, 1998
- Vasoconstrictor responses to the P2X-purinoceptor agonist (β, γ-methylene-L-ATP in human cutaneous and renal blood vesselsBritish Journal of Pharmacology, 1995